Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

华亦净 - NMPA Drug Approval Details

Approvals/NMPA/华亦净

Approved

生物制品

华亦净

上海华奥泰生物药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Jul 28, 2026
Approval ID: 8nb7BWIEJEc
Company: 上海华奥泰生物药业股份有限公司
Type: 生物制品

Approval Details

Approval Id: 8nb7BWIEJEc
Approval Number: 国药准字S20260056
Generic Name: 瑞西奇拜单抗注射液
Trade Name: 华亦净
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 西林瓶装注射剂型：120 mg（2 ml）/瓶
Reg Date: 2026-07-28
Company Name: 上海华奥泰生物药业股份有限公司
Company Address: 中国（上海）自由贸易试验区蔡伦路538号2幢1楼
Production Company Name: 浙江华海生物科技有限公司
Production Company Address: 浙江省杭州市钱塘区下沙街道呈瑞街278号

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 28, 2026

Approval ID

8nb7BWIEJEc

Type

生物制品

Back to NMPA Approvals